Aa
A
A
Close
Avatar universal
Therapeutic vaccine by Globeimmune
Data to be Presented Today at The Liver Meeting® 2012 in Boston

BOSTON, Nov. 10, 2012 – GlobeImmune, Inc. today announced that GI-13020, an investigational therapeutic vaccine designed using the company’s proprietary Tarmogen® product platform for the treatment of chronic hepatitis B virus (HBV) infection, demonstrated immunogenicity in two preclinical studies.  GI-13020, which is being developed in collaboration with Gilead Sciences, Inc., was found to activate antigen-specific CD4 and CD8 T cells, including those that respond to the HBV X, S and Core antigens, which are critical for the development of hepatitis B disease. These data will be presented today at The Liver Meeting 2012 in Boston.

A poster by Guo et al. will include data demonstrating antigen-specific T cell responses generated in mice immunized with GI-13020.  In addition, the data will show that GI-13020 significantly protected mice from tumors engineered to express HBV antigens.  In a second poster by Kemmler et al., Tarmogens elicited HBV-specific T cell responses ex vivo in samples collected from healthy individuals and donors with chronic HBV.  Further analyses showed that the Tarmogens were able to elicit functional immune responses in a clinically relevant model.

“Chronic HBV infection, which is characterized by inadequate and dysfunctional T cell responses against HBV antigens, can be effectively suppressed with long term antiviral therapy. However, there is a significant opportunity to improve permanent cure rates,” said David Apelian, M.D., Ph.D., Senior Vice President, Research & Development, and Chief Medical Officer of GlobeImmune. “We believe that administration of GI-13020 in patients whose disease is under virologic control with a direct acting antiviral agent may have the potential to increase hepatitis B surface antigen seroconversion rates, thus potentially allowing discontinuation of antiviral treatment.”

Link : http://www.globeimmune.com/archived-news/2012-press-releases/gi-13020-tarmogen-for-the-treatment-of-chronic-hepatitis-b-generates-antigen-specific-t-cell-responses-in-key-preclinical-studies/
Cancel
1 Answers
Page 1 of 1
Avatar universal
this is another hopeful drug.  
Comment
Cancel
Comment
Avatar universal
Comment
Comment
Submit Comment
Your Answer
Avatar universal
Answer
Know how to answer? Tap here to leave your answer...
Answer
Submit Answer
A
A
Blank
Weight Tracker
Weight Tracker
Start Tracking Now
Hepatitis B Community Resources